ProShare Advisors LLC Grows Position in Prothena Co. plc (NASDAQ:PRTA)

ProShare Advisors LLC boosted its stake in Prothena Co. plc (NASDAQ:PRTA) by 29.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 14,524 shares of the biotechnology company’s stock after buying an additional 3,312 shares during the quarter. ProShare Advisors LLC’s holdings in Prothena were worth $201,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Man Group plc raised its position in Prothena by 90.7% in the 4th quarter. Man Group plc now owns 77,430 shares of the biotechnology company’s stock valued at $1,072,000 after buying an additional 36,824 shares during the last quarter. Millennium Management LLC raised its position in Prothena by 9.3% in the 4th quarter. Millennium Management LLC now owns 123,005 shares of the biotechnology company’s stock valued at $1,704,000 after buying an additional 10,467 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Prothena by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 1,551 shares during the last quarter. Deutsche Bank AG raised its position in Prothena by 195.7% in the 4th quarter. Deutsche Bank AG now owns 95,970 shares of the biotechnology company’s stock valued at $1,329,000 after buying an additional 63,512 shares during the last quarter. Finally, Cary Street Partners Financial LLC purchased a new stake in shares of Prothena during the 4th quarter valued at $173,000. 97.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PRTA shares. Wall Street Zen raised Prothena from a “sell” rating to a “hold” rating in a research report on Monday, February 24th. Chardan Capital decreased their target price on Prothena from $40.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, May 27th. Bank of America reaffirmed an “underperform” rating on shares of Prothena in a research report on Wednesday, May 28th. Oppenheimer lowered Prothena from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 27th. Finally, Cantor Fitzgerald lowered Prothena from an “overweight” rating to a “neutral” rating in a research report on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Prothena presently has a consensus rating of “Hold” and an average price target of $31.50.

Prothena Stock Performance

Shares of PRTA opened at $4.59 on Monday. The business has a 50-day moving average of $8.88 and a 200 day moving average of $12.42. Prothena Co. plc has a fifty-two week low of $4.32 and a fifty-two week high of $25.42. The firm has a market cap of $247.07 million, a P/E ratio of -2.00 and a beta of 0.11.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.20). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $8.18 million. During the same period last year, the business posted ($1.34) EPS. The company’s revenue was up 5500.0% compared to the same quarter last year. As a group, research analysts predict that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.